{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:27:02Z","timestamp":1790440022398,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"am","delay-in-days":329,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004794","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006687","name":"Universit\u00e9 Claude Bernard Lyon 1","doi-asserted-by":"publisher","award":["FR 20\/02351"],"award-info":[{"award-number":["FR 20\/02351"]}],"id":[{"id":"10.13039\/501100006687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.antiviral.2020.104878","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T03:28:03Z","timestamp":1594783683000},"page":"104878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":151,"special_numbering":"C","title":["In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2"],"prefix":"10.1016","volume":"181","author":[{"given":"Andr\u00e9s","family":"Pizzorno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2159-6507","authenticated-orcid":false,"given":"Blandine","family":"Padey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9777-2968","authenticated-orcid":false,"given":"Julia","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8607-2827","authenticated-orcid":false,"given":"Thomas","family":"Julien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Traversier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Duli\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0762-832X","authenticated-orcid":false,"given":"Pauline","family":"Brun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Rosa-Calatrava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9393-7684","authenticated-orcid":false,"given":"Olivier","family":"Terrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104878_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.293","article-title":"Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases","volume":"5","author":"Al-Bari","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.antiviral.2020.104878_bib2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad-spectrum antiviral: an update","volume":"107","author":"Blaising","year":"2014","journal-title":"Antivir. Res."},{"issue":"19","key":"10.1016\/j.antiviral.2020.104878_bib3","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104878_bib4","article-title":"Favipiravir versus arbidol for COVID-19: a randomized clinical trial","volume":"2020","author":"Chen","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.antiviral.2020.104878_bib5","article-title":"Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial","volume":"2020","author":"Chen","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.antiviral.2020.104878_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104878_bib7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.antiviral.2020.104878_bib8","series-title":"Covid-19 living Data","year":"2020"},{"key":"10.1016\/j.antiviral.2020.104878_bib9","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/82191","article-title":"The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen","volume":"6","author":"Crotty","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2020.104878_bib10","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1099\/vir.0.034983-0","article-title":"Cyclosporin A inhibits the replication of diverse coronaviruses","volume":"92","author":"de Wilde","year":"2011","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2020.104878_bib11","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S1473-3099(14)70821-7","article-title":"Antiviral combinations for severe influenza","volume":"14","author":"Dunning","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104878_bib12","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104878_bib13","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob","volume":"46","author":"Furuta","year":"2002","journal-title":"Agents Chemother"},{"key":"10.1016\/j.antiviral.2020.104878_bib14","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/v10040184","article-title":"Arbidol (umifenovir): a broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses","volume":"10","author":"Haviernik","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2020.104878_bib15","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.antiviral.2020.104878_bib16","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","article-title":"SynergyFinder: a web application for analyzing drug combination dose\u2013response matrix data","volume":"33","author":"Ianevski","year":"2017","journal-title":"Bioinformatics"},{"key":"10.1016\/j.antiviral.2020.104878_bib17","article-title":"The effect of Arbidol Hydrochloride on reducing mortality of Covid-19 patients: a retrospective study of real world date from three hospitals in Wuhan","volume":"2020","author":"Liu","year":"2020","journal-title":"medRxiv"},{"issue":"6","key":"10.1016\/j.antiviral.2020.104878_bib18","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1473-3099(20)30232-2","article-title":"Viral dynamics in mild and severe cases of COVID-19","volume":"20","author":"Liu","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104878_bib19","article-title":"Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19","volume":"2020","author":"Magagnoli","year":"2020","journal-title":"medRxiv"},{"issue":"10229","key":"10.1016\/j.antiviral.2020.104878_bib20","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.antiviral.2020.104878_bib21","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104878_bib22","article-title":"Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia","volume":"2020","author":"Pizzorno","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.antiviral.2020.104878_bib23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fimmu.2019.00060","article-title":"Repurposing of drugs as novel influenza inhibitors from clinical gene expression infection signatures","volume":"10","author":"Pizzorno","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.antiviral.2020.104878_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011159","article-title":"New world hantaviruses activate IFN\u03bb production in type I IFN-deficient Vero E6 cells","volume":"5","author":"Prescott","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2020.104878_bib25","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.177.4050.705","article-title":"Broad-spectrum antiviral activity of virazole: 1-f8- D-ribofuranosyl- 1,2,4-triazole- 3-carboxamide","volume":"177","author":"Sidwell","year":"1972","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2020.104878_bib26","author":"Solidarity"},{"key":"10.1016\/j.antiviral.2020.104878_bib27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.antiviral.2015.12.012","article-title":"Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses","volume":"126","author":"Varghese","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104878_bib28","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.1128\/JVI.01382-16","article-title":"The antiviral alkaloid berberine reduces chikungunya virus-induced mitogen-activated protein kinase signaling","volume":"90","author":"Varghese","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2020.104878_bib29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.antiviral.2020.104878_bib30","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1002\/ptr.6196","article-title":"Anti-influenza activity of berberine improves prognosis by reducing viral replication in mice","volume":"32","author":"Yan","year":"2018","journal-title":"Phytother. Res. PTR"},{"key":"10.1016\/j.antiviral.2020.104878_bib31","doi-asserted-by":"crossref","first-page":"m1443","DOI":"10.1136\/bmj.m1443","article-title":"Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study","volume":"369","author":"Zheng","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.antiviral.2020.104878_bib32","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:31:51Z","timestamp":1759062711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354220302928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":32,"alternative-id":["S0166354220302928"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104878","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104878"}}